For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink:https://www.kuickresearch.com/report-global-cancer-cdk-inhibitors-market-and-clinical-pipeline-outlook-2022.php
Table of Contents
1. Cyclin Dependent Kinase Inhibitors andndash;An Introduction to a Promising Cancer Therapeutic
1.1 History of Discoveries Leading to Cyclin Dependent Kinase Inhibitor Drug
1.2 An Insight into Cell Cycle, Cyclin and the Role of CDKs
1.3 Cyclin Dependent Kinase Inhibitors for Cancer – An Overview
2. Cyclin Dependent Kinase Pathway as Targets for Cancer Therapy
2.1 CDK Pathway and Cell Cycle Checkpoints
2.2 Role of Cyclin Dependent Kinases in Carcinogenesis
2.3 Cyclin Dependent Kinases Associated With Various Cancers
3. Selectivity and Working Mechanism of a Cancer CDKs Inhibitor
4. Types of CDK Inhibitors
4.1 ATP Competitive CDK Inhibitors
4.2 ATP Non Competitive Inhibitors
4.3 Allosteric Inhibitors
5. Recent Advances in the CDKs Related Cancer Therapy
5.1 CDK 4/6 in Breast Cancer
5.2 Role of CDKs in Hematological Malignancies
6. CDK Inhibitors as Combinational Cancer Therapeutic
7. Current Market Scenario of Cancer CDKs inhibitors
7.1 Commercial Aspects of CDKs Inhibitor
7.2 Key Market Players in the Cancer CDKs Inhibitor Market
7.3 Global Cancer CDK-Inhibitors Pipeline Overview
8. Marketed Cancer CDK Inhibitors Clinical Insight
8.1 Palbociclib (Ibrance)
8.2 Ribociclib (Kisqali)
9. Price Analysis of Cancer CDKs Inhibitors
9.1 Commercially Available CDK Inhibitors Price Analysis
9.1.1 Cost of Approved Cancer CDKs Inhibitor
9.1.2 Average Cost of CDKs Inhibitors Currently Under Research
9.2 Comparison of Cancer CDKs inhibitor to other Cancer Drugs and Therapies
10. Driving Factors of the Cancer CDKs Inhibitors Market
10.1 Accelerated Approval of Previously Introduced CDKs Inhibitor for Breast Cancer- Ibrance
10.2 Increasing Prevalence of Cancer
10.3 Presence of a Robust Clinical Pipeline
10.4 Advancement in Research and Development
10.5 High Unmet Medical Needs
11. CDK Inhibitors Market Challenges
11.1 High Cost Factor Associated with Cancer CDKs Inhibitor
11.2 Scientific and Technical Limitations
11.3 Side Effects and unreliable Efficacy
11.4 Competition from other Cancer Therapeutic Segments
11.5 Slow FDA Approvals
11.6 Commercial Challenges
12. Anticipation Regarding the Future of CDKs Inhibitor Cancer Therapy Market
13. Global Cancer CDK Inhibitors Clinical Trials Insight by Company, Indication and Phase
13.1 Preclinical
13.2 Phase-I
13.3 Phase-I/II
13.4 Phase-II
13.5 Phase-III
13.6 Preregistration
14. Competitive Landscape
14.1 Amgen
14.2 Anygen
14.3 Astex
14.4 Bayer Pharmaceuticals
14.5 BioCAD
14.6 Cyclacel
14.7 Eli andndash; Lilly
14.8 G1 Therapeutics
14.9 Nerviano Medical Science
14.10 Merck
14.11 Pfizer
14.12 Piramal Life
14.13 Syros Pharmaceuticals
14.14 Sanofi-Aventis
Figure 1-1: Timeline Depicting CDK’s Development
Figure 1-2: Cyclin – The Key Regulators of Cell Cycle
Figure 1-3: Cyclin Dependent Kinase and Their cyclin Regulatory Subunits
Figure 2-1: Tumor Proliferation Due to Hyperactive Kinase
Figure 3-1: Mechanism of Cell Cycle Inhibition by a CDKs Inhibitor
Figure 4-1 : Allosteric Inhibitors in Action
Figure 5-1: Flowchart depicting CDK 4/6 Inhibitor in Action
Figure 5-2: CDK 4/6 Inhibition Preventing Tumor Proliferation
Figure 7-1: Global – Ibrance CDK Inhibitor Revenue (US$ Billion), 2017
Figure 7-2: Global – Cancer CDK Inhibitors Pipeline by Phase (%), 2017 till 2022
Figure 7-3: Global – Cancer CDK Inhibitors Pipeline by Phase (Number), 2017 till 2022
Figure 7-4: Global – Cancer CDK Inhibitors Pipeline by Phase (%), 2017 till 2022
Figure 7-5: Global – Cancer CDK Inhibitors Pipeline by Phase (Number), 2017 till 2022
Figure 9-1: Global- Ibrance Revenue (US$ Million), Q1’2015-Q2’2017
Figure 9-2: Ibrance- Average Treatment Cost (US$), 2017
Figure 9-3: Kisqali andndash; Average Treatment Cost (US$), 2017
Figure 9-4: Abemaciclib – Average Treatment Cost (US$), 2017
Figure 9-5: Seliciclib- Price Analysis by 10mg, 50mg and 200mg Tablet for CDK5 Inhibitor (US$), 2017
Figure 9-6: Dinaciclib – Price Analysis by 5mg, 25mg and 50mg Tablet for CDK1/2, CDK5 and CDK9 Inhibitor (US$), 2017
Figure 9-7: SNS-013-Price Analysis by 5mg, 10mg and 50mg Tablet for CDK 7/9/2 Inhibitor (US$), 2017
Figure 9-8: Milciclib- Price Analysis by 5mg and 10mg Tablet for CDK 2/7/4/5 Inhibitor (US$), 2017
Figure 9-9: Flavopiridol -Price Analysis by 5mg, 25mg and 100mg Tablet for CDK 1/2/4/6 Inhibitor (US$), 2017
Figure 9-10: Comparative Price of Approved CDKs Inhibitors (US$/Month), 2017
Figure 9-11: Comparative Cost Analysis – Average Price of Existing Breast Cancer Drugs and CDK inhibitors (US$) , 2017
Figure 9-12: Comparative Cost Analysis – CDK Inhibitor (Ibrance) and other Targeted Therapy Drugs (US$), 2017
Figure 9-13: Comparative Cost Analysis – CDK Inhibitors and Commonly Recommended Cancer Therapeutics (US$), 2017
Figure 9-14: Comparative Cost Analysis – CDKs Inhibitor and the Best Available Therapy for Breast Cancer (US$), 2017
Figure 10-1: Driving Factors of the Cancer CDKs Inhibitors Market
Figure 10-2: Global – Breast Cancer Incidence (‘000’), 2015
Figure 10-3: Global-Cancer Deaths (%), 2016
Figure 11-1: Global – Cancer CDK Inhibitors Market Challenge
Figure 12-1: Global- CDKs Inhibitors Market Revenue Forecast (US$ Billion), 2022
Figure 12-2: Global – Expected Market Share of CDKs Inhibitor (%), 2022
